ANN ARBOR, Mich., Feb. 20 /PRNewswire/ -- Rubicon Genomics today announced the formation of a new Scientific Advisory Board to support its recent advances in cancer molecular diagnostics.
The company appointed Arul M. Chinnaiyan, M.D., Ph.D. as its first new Molecular Diagnostics Scientific Advisory Board Member. Dr. Chinnaiyan is the S.P. Hicks Endowed Professor of Pathology and Associate Professor of Urology at the University of Michigan Medical School. He is the co-Director of the Division of Pathology Informatics and Director of the Cancer Bioinformatics Core. He is a recognized leader in the field and has led the characterization of a number of biomarkers of prostate cancer including AMACR, EZH2, and hepsin. Most recently, his laboratory identified gene fusion of TMPRSS2 to ETS family of transcription factors in prostate cancer, potentially redefining the molecular basis of prostate cancer as well as other common epithelial cancers. Dr. Chinnaiyan has received numerous awards, authored more than 100 publications, holds several U.S. patents, and is funded by the National Institute of Health, the American Cancer Society, and the Department of Defense.
"We feel both privileged and fortunate to have Dr. Chinnaiyan joining our New Scientific Advisory Board for Molecular Diagnostics," said Fred G. Beyerlein, President & CEO of Rubicon. "Our association with Dr. Chinnaiyan, his labs, and the University of Michigan spans several years and has proven to be a fruitful collaboration. Our mutual interests in developing breakthroughs in the early detection, monitoring, and deeper understanding of cancer have always been in alignment. We are looking forward to his insights and contributions as a member of our newly formed Molecular Diagnostics Scientific Advisory Board."
About Rubicon Genomics, Inc.
Rubicon, located in Ann Arbor, MI, is focused on the development of highly sensitive and highly specific non-invasive tests for cancer and other diseases using its proprietary MethylPlex(TM) technology. Utilizing the MethylPlex platform the company has discovered and developed proprietary tumor markers and patterns of tumor markers. The Company is a leader in the development of breakthrough methods of detecting the pattern of genetic, epigenetic, and expression changes in tumor cells as well as developing kits and services to facilitate gene-based research and drug development. For additional information please visit the Rubicon website: http://rubicongenomics.com or telephone 734-677-6210.
Rubicon Genomics, Inc.CONTACT: Fred G. Beyerlein, President & CEO of Rubicon Genomics, Inc.,+1-734-677-2890
Web site: http://rubicongenomics.com/
